ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cazzola, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cazzola, M.
Eur Respir J 2008; 31:416-469
Copyright ©ERS Journals Ltd 2008

Outcomes for COPD pharmacological trials: from lung function to biomarkers

M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, P. W. Jones, D. A. Mahler, B. Make, M. Miravitlles, C. P. Page, P. Palange, D. Parr, M. Pistolesi, S. I. Rennard, M. P. Rutten-van Mölken, R. Stockley, S. D. Sullivan, J. A. Wedzicha, E. F. Wouters on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD

For affiliations, please see the Acknowledgements section.

CORRESPONDENCE: M. Cazzola, Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy. Fax: 39 0672596621. E-mail: mario.cazzola{at}uniroma2.it; mcazzola{at}qubisoft.it

Received: July 31, 2006
Accepted November 20, 2007

The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
S. I. Rennard and J. Vestbo
Natural Histories of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 15, 2008; 5(9): 878 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
B. J. Make and F. J. Martinez
Assessment of Patients with Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 15, 2008; 5(9): 884 - 890.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. B. Soriano and A. Agusti
The of COPD: or balancing repair (yang) and inflammation (yin)
Eur. Respir. J., December 1, 2008; 32(6): 1426 - 1427.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. F. P. Man, L. Xing, J. E. Connett, N. R. Anthonisen, R. A. Wise, D. P. Tashkin, X. Zhang, R. Vessey, T. G. Walker, B. R. Celli, et al.
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?
Eur. Respir. J., December 1, 2008; 32(6): 1451 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G. M Turino
COPD and biomarkers: the search goes on
Thorax, December 1, 2008; 63(12): 1032 - 1034.
[Full Text] [PDF]

Home page
 ThoraxHome page
D A Lomas, E K Silverman, L D Edwards, B E Miller, H O Coxson, R Tal-Singer, and on behalf of the Evaluation of COPD Longitudinally
Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort
Thorax, December 1, 2008; 63(12): 1058 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. B. Drummond, E. C. Dasenbrook, M. W. Pitz, D. J. Murphy, and E. Fan
Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis
JAMA, November 26, 2008; 300(20): 2407 - 2416.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Luisetti, S. Ma, P. Iadarola, P. J. Stone, S. Viglio, B. Casado, Y. Y. Lin, G. L. Snider, and G. M. Turino
Desmosine as a biomarker of elastin degradation in COPD: current status and future directions
Eur. Respir. J., November 1, 2008; 32(5): 1146 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Stanescu
Lung volume measurements
Eur. Respir. J., August 1, 2008; 32(2): 527 - 527.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Cazzola, V. Brusasco, and F. J. Martinez
From the authors
Eur. Respir. J., August 1, 2008; 32(2): 528 - 528.
[Full Text] [PDF]

Home page
 ChestHome page
M. Cazzola and M. G. Matera
To Add, or Not To Add an Inhaled Corticosteroid in Moderate COPD: That Is the Question
Chest, August 1, 2008; 134(2): 223 - 225.
[Full Text] [PDF]

Home page
 ChestHome page
D. D. Sin and S. F. P. Man
Biomarkers in COPD: Are We There Yet?
Chest, June 1, 2008; 133(6): 1296 - 1298.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Dahl
Biomarkers for Chronic Obstructive Pulmonary Disease: Surfactant Protein D and C-Reactive Protein
Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1177 - 1178.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the European Respiratory Society.